Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00071799 · ClinicalTrials.gov registry record · Phase 3
A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care
A Phase 3 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 3
- Development phase
- 358
- Enrollment target
NCT00071799 is a Phase 3 study that has completed, run by Celgene. The registered enrollment target is 358 participants.
The verdict
NCT00071799, a Phase 3 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 358 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether patients with high-risk myelodysplastic syndromes (MDS) treated with azacitidine have improved survival compared to conventional care treatments. The study will also assess the effect of treatments on response, duration of response, and transformation to acute myeloid leukemia (AML). The study will continue for 12 months following last patient enrolled. See study AZA PH GL 2003 CL 001 E for information about the extension to this study.
Interventions
- DRUG Azacitidine
- OTHER Physician Choice
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 358 participants |
| Start Date | 2003-11-01 |
| Est. Completion | 2007-07-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00071799
The ClinicalTrials.gov registry entry for NCT00071799 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 358 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azacitidine is the first listed.
NCT00071799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00071799 about?
NCT00071799 is a clinical study titled "A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care". The purpose of this study is to determine whether patients with high-risk myelodysplastic syndromes (MDS) treated with azacitidine have improved survival compared to conventional care treatments. The study will also assess the effect of treatments on response, duration of response, and transformatio...
What is the current status of trial NCT00071799?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 358 participants. The study started on 2003-11-01. Estimated completion is 2007-07-01.
What interventions are being tested in trial NCT00071799?
The interventions under investigation include: Azacitidine (DRUG), Physician Choice (OTHER).
Who is sponsoring clinical trial NCT00071799?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.